It looks like CASI is now planning to progress Marqibo in China. There is a hint they expect approval in China this year.
"CASI’s management sees its opportunity as long-term. We agree with CASI’s decision as it will likely result in the best combination of revenue growth and solid profitability while moderating capital needs over the intermediate term."
"While this change is significant, we believe that there is room for upside as the company moves its licensed and proprietary hematology portfolio closer to commercialization."
"We forecast $7.1m in Evomela sales for 2020 and total sales of $12.5 million assuming approval and commercialization for Marqibo and Zevalin."
News 
Market Data 
Discover 
